

# EURACAN

## EUROPEAN REFERENCE NETWORK

### ON RARE SOLID ADULT CANCERS



M. Rogasik<sup>1\*</sup>, P.A. Casali<sup>2</sup>, M.Seckl<sup>3</sup>, J.Gietema<sup>4</sup>, M Caplin<sup>5</sup>, L. Wyrwicz<sup>6</sup>, E. Baudin<sup>7</sup>, L. Licitra<sup>2</sup>, N Girard<sup>8</sup>, D.Schadendorf<sup>9</sup>, M.J. Van den Bent<sup>10</sup>, P. Hohenberger<sup>11</sup>, K. Oliver<sup>12</sup>, I. Manneh Vangramberen<sup>13</sup>, A Weinman<sup>14</sup>, S. Lejeune<sup>15</sup>, B. Hassan<sup>16</sup>, D. de Valeriola<sup>17</sup>, J. Lovey<sup>17</sup>, A.P. Dei Tos<sup>18</sup>, A. Araujo<sup>19</sup>, J. Martin Broto<sup>20</sup>, H.Falconer<sup>21</sup>, M.Kasler<sup>22</sup>, K. Kopeckova<sup>23</sup>, A. Tamasauskas<sup>24</sup>, I. Vergote<sup>25</sup>, J.Y. Blay<sup>1</sup>.


<sup>1</sup>Centre Léon Bérard, Lyon, France; <sup>2</sup>Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; <sup>3</sup>Imperial College Hospitals NHS Trust, London, United Kingdom; <sup>4</sup>University Medical Centre, Groningen, The Netherlands; <sup>5</sup>Royal Free London NHS Foundation Trust, London United Kingdom; <sup>6</sup>Maria Sklodowska Curie Institute - Oncology Centre, Warsaw, Poland; <sup>7</sup>Institut Gustave Roussy, Villejuif, France; <sup>8</sup>Institute Curie, Paris, France; <sup>9</sup>University Hospital Essen, Essen, Germany, <sup>10</sup>Eramus MC, Rotterdam, The Netherlands; <sup>11</sup>Mannheim University Medical Centre, Mannheim, Germany; <sup>12</sup>International Brain Tumour Alliance (IBTA); Tadworth, United Kingdom; <sup>13</sup>European Cancer Patient Coalition (ECPC), Brussels, Belgium; <sup>14</sup>European Organisation for rare diseases, (EURORDIS), Paris, France; <sup>15</sup>European Organisation for Research and Treatment of Cancer (EORTC), Brussels, Belgium; <sup>16</sup>Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom; <sup>17</sup>Organisation of European Cancer Institutes (OECI), Brussels, Belgium; <sup>18</sup>Azienda ULSS 2 Mara Trevigiana, Treviso, Italy; <sup>19</sup>Centro Hospitalar do Porto, Porto, Portugal, <sup>20</sup>Complejo Hospitalario regional Virgen del Rocio, Seville, Spain, <sup>21</sup>Karolinska University Hospital, Karolinska, Sweden; <sup>22</sup>National Institute of Oncology, Budapest, Hungaria, <sup>23</sup>University Hospital Motol, Prague, Czech Republic, <sup>24</sup>Hospital of Lithuanian University of Health Sciences, Kaunas, Lithuania, <sup>25</sup>Leuven Cancer Institute, Leuven, Belgium.

#### INTRODUCTION

ERNs are virtual networks involving healthcare providers across Europe.

**EURACAN** is the ERN on rare adult solid cancers and it gathers together 66 centres from 17 European countries. It aims to improve the quality of care and outcome of patients with rare adult solid cancers in the EU: **diagnosis, treatment management, knowledge, research and communication on all adult solid rare cancers for patients, families, physicians and all stakeholders;**

**EURACAN EUROPEAN COVERAGE:** Healthcare providers were identified on the basis of documented expertise, accrual in rare cancers, and endorsement by their Member State



**METHODOLOGY:** Patients across the EU will have access to the best expertise available on diagnosis and treatments through the Clinical Patient Management System (CPMS). The CPMS allows healthcare providers from all over the EU to organise virtual consultations and share experience together across national borders



**EURACAN TARGETED RAC:** **EURACAN** groups all rare cancers solid adult into **ten “domains”** corresponding to the RARECARE list of rare cancers based on the ICD-O



EURACAN invited **Associated Partners** from major scientific societies and leading patient advocacy organisations to participate in the different network bodies.



#### OUTCOMES

- Homogenisation** of Clinical Practice Guidelines across all domains
- Development of a public **website** translated in ten languages and a Facebook page and a Twitter account.
- First **enrolment of patients** in the CPMS started in December 2017

#### CONCLUSION

**EURACAN** provides a unique network to European patients affected with rare cancers, from all member states, enabling access to optimal care, rare resources, education, innovation and research. Additional affiliated centres will join EURACAN in due course to further extend the network’s outreach and increase coverage.

Prof Jean-Yves Blay: Coordinator [jean-yves.blay@lyon.unicancer.fr](mailto:jean-yves.blay@lyon.unicancer.fr);  
Muriel Rogasik: Network Manager [muriel.rogasik@lyon.unicancer.fr](mailto:muriel.rogasik@lyon.unicancer.fr);  
Françoise Ducimetière: [francoise.ducimetiere@lyon.unicancer.fr](mailto:francoise.ducimetiere@lyon.unicancer.fr);  
Magali Bayssiére: administrative affairs [magali.BAYSSIERE@lip-LYON1.fr](mailto:magali.BAYSSIERE@lip-LYON1.fr).